Validation of a proposed warfarin dosing algorithm based on the genetic make-up of egyptian patients

Molecular Diagnosis and Therapy

Volumn 17, Issue 6, 2013, Pages 381-390

  Ekladious, Sherif M M ^a   Issac, Marianne Samir M ^a   Sharaf, Sahar Abd El Atty ^a   Abou Youssef, Hazem S ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 2C9; VITAMIN K EPOXIDE REDUCTASE; WARFARIN;

ADULT; ALGORITHM; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL ARTICLE; COST; COST EFFECTIVENESS ANALYSIS; FEMALE; GENOTYPE; HEREDITY; HUMAN; HUMAN GENETICS; MAINTENANCE DRUG DOSE; MALE; MIDDLE AGED; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; EGYPT; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; VITAMIN K EPOXIDE REDUCTASES; WARFARIN;

EID: 84890507752     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-013-0046-3     Document Type: Article

References (52)

1. You J, Wong R, Waye M, et al. Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. J Thromb Thrombolysis. 2011;31:113-8.
2. Sasaki T, Tabuchi H, Higuchi S, et al. Warfarin-dosing algorithm based on a population pharmacokinetic/pharmacodynamic model combined with Bayesian forecasting. Pharmacogenomics. 2009;10(8):1257-66.
3. Lazo-Langner A, Kovacs MJ. Predicting warfarin dose. Curr Opin Pulm Med. 2010;16(5):426-31.
4. Loebstein R, Yonath H, Peleg D, et al. Interindividual variability in sensitivity to warfarin - nature or nurture? Clin Pharmacol Ther. 2001;70:159-64.
5. Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res. 2007;120:1-10.
6. Crawford JM, Aspinall MG. The business value and cost-effectiveness of genomic medicine. Pers Med. 2012;9(3):265-86.
7. Shuen AY, Wong BY, Fu L, Selby R, et al. Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic. Clin Biochem. 2012;45:397-401.
8. Skov J, Bladbjerg E-M, Leppin A, et al. The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. Thromb Res. 2013;131:125-9.
9. Flockhart DA, O'Kane D, Williams MS, et al. On behalf of the ACMG Working Group on Pharmacogenetic Testing of CYP2C9, VKORC1 Alleles for Warfarin Use. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genet Med. 2008;10:139-50.
10. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427:537-41.
11. Suttie JW. The biochemical basis of warfarin therapy. Adv Exp Med Biol. 1987; 214:3-16.
12. Stenflo J, Fernlund P, Egan W, et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A. 1974; 71:2730-3.
13. Rettie AE, Tai G. The pharmocogenomics of warfarin: closing in on personalized medicine. Mol Interv. 2006;6:223-7.
14. Yoshizawa M, Hayashi H, Tashiro Y, et al. Effect of VKORC1-1639 G>A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients. Thromb Res. 2009;124:161-6.
15. Cho HJ, Sohn KH, Park HM, et al. Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics. 2007;8:329-37.
16. Huang SW, Li Q, Zhu S-Y, Li L, et al. SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement. Clin Chem Lab Med. 2009;47(1):26-31.
17. Gage BF, Lesko LJ. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J Thromb Thrombolysis. 2008; 25:45-51. doi: 10.1007/s11239-007-0104-y.
18. Gage BF, Eby C, Johnson JA, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008;84:326-31.
19. The International Warfarin Pharmacogenetics Consortium. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753-64.
20. Gage BF. Warfarin dosing. Washington University, St Louis. http://www.warfarindosing.org/Source/Home.aspx. Accessed Jun 2013.
21. US Food and Drug Administration. Table of valid genomic biomarkers in the context of approved drug labels. http://www.fda.gov/cder/genomics/genomic- biomarkers-table.htm. Updated 10 Sep 2008.
22. Miao L, Yang J, Huang C, et al. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a newdosing regimen in Chinese patients. Eur J Clin Pharmacol. 2007;63:1135-41.
23. Suriapranata IM, Tjong WY, Wang T, et al. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians. BMC Med Genet. 2011;12:80.
24. Herman D, Locatelli I, Grabnar I, Peternel P, et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J. 2005;5(3):193-202.
25. Rusdiana T, Araki T, Nakamura T, et al. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population. Eur J Clin Pharmacol. 2013;69:395-405.
26. Shahin MH, Khalifa SI, Gong Y, et al. Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics. 2011;21(3):130-5.
27. El Din MS, Amin DG, Ragab SB, et al. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen. Int J Lab Hematol. 2012;34:517-24.
28. D'Andrea G, D'Ambrosio R, Di Perna P, Chetta M, Santacroce R, Brancaccio V, Grandone E, Margaglione M. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose anticoagulant effect of warfarin. Blood. 2005;105:645-9.
29. Daly A, King B. Pharmacokinetics of oral anticoagulants. Pharmacogenetics. 2003;13:247-52.
30. Bazan NS, Sabry NA, Rizk A, et al. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients. Int J Clin Pharm. 2012;34:837-44.
31. Gage BF, Eby C, Milligan PE, et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost. 2004;91:87-94.
32. D'Andrea G, D'Ambrosio R, Margaglione M. Oral anticoagulants: pharmacogenetics relationship between genetic and non-genetic factors. Blood Rev. 2008; 22(3):127-40.
33. Teh LK, Langmia IM, Fazleen Haslinda MH, et al. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin. J Clin Pharm Ther. 2012;37:232-6.
34. Cini M, Legnani C, Cosmi B, et al. A new warfarin dosing algorithm including VKORC1 3730 G >A polymorphism: comparison with results obtained by other published algorithms. Eur J Clin Pharmacol. 2012;68(8):1167-74.
35. Xu D, Liu Y, Zhong S-L, et al. Effect of demographic factors on warfarin dosing in patients after cardiac valve replacement. J Practical Med. 2010;5:750-753. http://www.123xu.com/gl/9009.htm. Accessed 20 May 2012.
36. Jonas DE, McLeod HL. Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci. 2009;30(7):375-86.
37. Namazi S, Azarpira N, Hendijani F, et al. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran. Clin Ther. 2010;32(6):1050-60.
38. Habib Z. Haptoglobin polymorphism in Egyptians. Ann Hum Biol. 1983; 10(4):385-87.
39. Yuan H, Chen J, Lee M, Wung J, et al. A novel functional VKORC1 promoter polymorphism is associated with interindividual and interethnic differences in warfarin sensitivity. Hum Mol Genet. 2005;14:1745-51.
40. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352:2285-93.
41. Gu Q, Kong Y, Schneede J, et al. VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China. Eur J Clin Pharmacol. 2010; 66:1217-27.
42. Wadelius M, Sörlin K, Wallerman O, et al. Warfarin sensitivity related toCYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics. 2004;4(1):40-8.
43. Wajih N, Sane DC, Hutson SM, et al. The inhibitory effect of calumenin on the vitamin K-dependent γ-carboxylation system. Characterization of the system in normal and warfarin resistant rats. J Biol Chem. 2004;279(24):25276- 83.
44. Wadelius M, Chen LY, Downes K, et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J. 2005;5(4):262-70.
45. Voora D, Koboldt DC, King CR, et al. A polymorphism in the VKORC1-regulator calumenin predicts higher warfarin doses in African-Americans. Clin Pharmacol Ther. 2010;87(4):445-51.
46. Wadelius M. Use of pharmacogenetics in guiding treatment with warfarin. Clin Chem. 2009;55:709-11.
47. Rosove MH, Grody WW. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Ann Intern Med. 2009;151:270-3.
48. Eckman MH, Rosand R, Greenberg SM, et al. Cost effectiveness of using pharmacogenetic information in warfarin dosing for patients with non-valvular atrial fibrillation. Ann Intern Med. 2009;150:73-83.
49. You JHS, Tsui KKN, Wong RSM, et al. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients initiating warfarin therapy. Clin Pharmacol Ther. 2009;86:540-7.
50. Vassy JL. Can genetic information change patient behavior to reduce type 2 diabetes risk? Pers Med. 2013;10(1):9-12.
51. Toriello M, Meccariello P, Mazzaccara C, et al. Comparison of the TaqMan and light cycler systems in pharmacogenetic testing: evaluation of CYP2C9*2/*3 polymorphisms. Clin Chem Lab Med. 2006;44:285-7.
52. Caldwell MD, Awad T, Johnson JA, et al. CYP4F2 genetic variant alters required warfarin dose. Blood. 2008;111:4106-12.